AAPL   324.32 (-0.25%)
MSFT   183.65 (-0.92%)
FB   227.59 (-1.12%)
GOOGL   1,422.94 (-1.13%)
NVDA   352.41 (+0.46%)
GE   7.50 (+1.77%)
AMD   52.63 (-0.19%)
T   31.57 (+0.19%)
ACB   14.14 (-1.12%)
F   6.34 (+2.42%)
GILD   75.43 (+1.38%)
DIS   123.46 (+1.05%)
NFLX   419.14 (-0.67%)
BA   184.21 (+6.38%)
AAPL   324.32 (-0.25%)
MSFT   183.65 (-0.92%)
FB   227.59 (-1.12%)
GOOGL   1,422.94 (-1.13%)
NVDA   352.41 (+0.46%)
GE   7.50 (+1.77%)
AMD   52.63 (-0.19%)
T   31.57 (+0.19%)
ACB   14.14 (-1.12%)
F   6.34 (+2.42%)
GILD   75.43 (+1.38%)
DIS   123.46 (+1.05%)
NFLX   419.14 (-0.67%)
BA   184.21 (+6.38%)
AAPL   324.32 (-0.25%)
MSFT   183.65 (-0.92%)
FB   227.59 (-1.12%)
GOOGL   1,422.94 (-1.13%)
NVDA   352.41 (+0.46%)
GE   7.50 (+1.77%)
AMD   52.63 (-0.19%)
T   31.57 (+0.19%)
ACB   14.14 (-1.12%)
F   6.34 (+2.42%)
GILD   75.43 (+1.38%)
DIS   123.46 (+1.05%)
NFLX   419.14 (-0.67%)
BA   184.21 (+6.38%)
AAPL   324.32 (-0.25%)
MSFT   183.65 (-0.92%)
FB   227.59 (-1.12%)
GOOGL   1,422.94 (-1.13%)
NVDA   352.41 (+0.46%)
GE   7.50 (+1.77%)
AMD   52.63 (-0.19%)
T   31.57 (+0.19%)
ACB   14.14 (-1.12%)
F   6.34 (+2.42%)
GILD   75.43 (+1.38%)
DIS   123.46 (+1.05%)
NFLX   419.14 (-0.67%)
BA   184.21 (+6.38%)
Log in

NASDAQ:YMABY-mAbs Therapeutics Stock Price, Forecast & News

$41.04
-1.19 (-2.82 %)
(As of 06/4/2020 12:32 PM ET)
Add
Compare
Today's Range
$40.81
Now: $41.04
$42.93
50-Day Range
$30.00
MA: $36.10
$42.94
52-Week Range
$14.16
Now: $41.04
$43.80
Volume2,247 shs
Average Volume283,698 shs
Market Capitalization$1.63 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.38
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
Read More
Y-mAbs Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:YMAB
CUSIPN/A
CIKN/A
Phone646-885-8505

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.01 per share

Profitability

Net Income$-81,030,000.00

Miscellaneous

Employees32
Market Cap$1.63 billion
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive YMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

How has Y-mAbs Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Y-mAbs Therapeutics' stock was trading at $22.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, YMAB shares have increased by 78.6% and is now trading at $41.04. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Y-mAbs Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Y-mAbs Therapeutics.

When is Y-mAbs Therapeutics' next earnings date?

Y-mAbs Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Y-mAbs Therapeutics.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) posted its earnings results on Thursday, May, 7th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by $0.04. View Y-mAbs Therapeutics' earnings history.

What price target have analysts set for YMAB?

8 equities research analysts have issued 12-month price objectives for Y-mAbs Therapeutics' stock. Their forecasts range from $39.00 to $52.00. On average, they anticipate Y-mAbs Therapeutics' stock price to reach $44.60 in the next twelve months. This suggests a possible upside of 8.7% from the stock's current price. View analysts' price targets for Y-mAbs Therapeutics.

Has Y-mAbs Therapeutics been receiving favorable news coverage?

Media stories about YMAB stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Y-mAbs Therapeutics earned a coverage optimism score of -3.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutY-mAbs Therapeutics.

Are investors shorting Y-mAbs Therapeutics?

Y-mAbs Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 2,300,000 shares, an increase of 14.4% from the April 15th total of 2,010,000 shares. Based on an average trading volume of 222,000 shares, the days-to-cover ratio is presently 10.4 days. Currently, 9.3% of the shares of the company are sold short. View Y-mAbs Therapeutics' Current Options Chain.

Who are some of Y-mAbs Therapeutics' key competitors?

What other stocks do shareholders of Y-mAbs Therapeutics own?

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the following people:
  • Mr. Thomas Gad, Founder, Chairman, Pres & Head of Bus. Devel. (Age 48)
  • Dr. Claus Juan Møller San Pedro, CEO & Director (Age 56)
  • Mr. Bo Kruse, Exec. VP, Sec., Treasurer, CFO & Director (Age 47)
  • Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 44)
  • Dr. Torben Lund-Hansen, Sr. VP & Head of Technical Operations (Age 68)

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (6.90%), BlackRock Inc. (4.98%), Cormorant Asset Management LP (4.36%), Alliancebernstein L.P. (2.36%), State Street Corp (1.98%) and Loomis Sayles & Co. L P (1.78%). Company insiders that own Y-mAbs Therapeutics stock include Ashu Tyagi, Bo Kruse, James Healy, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Moller San Pedro Claus Juan, Pedro Claus Juan Moller-San and Thomas Gad. View institutional ownership trends for Y-mAbs Therapeutics.

Which major investors are selling Y-mAbs Therapeutics stock?

YMAB stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Deutsche Bank AG, Two Sigma Investments LP, Perceptive Advisors LLC, Perceptive Advisors LLC, Squarepoint Ops LLC, BlackRock Inc., and Burrage Capital Management LLC. Company insiders that have sold Y-mAbs Therapeutics company stock in the last year include Bo Kruse, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, and Thomas Gad. View insider buying and selling activity for Y-mAbs Therapeutics.

Which major investors are buying Y-mAbs Therapeutics stock?

YMAB stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Loomis Sayles & Co. L P, Aviva PLC, Cormorant Asset Management LP, New York State Common Retirement Fund, Sphera Funds Management LTD., Alliancebernstein L.P., and Tekla Capital Management LLC. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include Ashu Tyagi, James Healy, Moller San Pedro Claus Juan, and Pedro Claus Juan Moller-San. View insider buying and selling activity for Y-mAbs Therapeutics.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $41.04.

How big of a company is Y-mAbs Therapeutics?

Y-mAbs Therapeutics has a market capitalization of $1.63 billion. The company earns $-81,030,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. Y-mAbs Therapeutics employs 32 workers across the globe.

What is Y-mAbs Therapeutics' official website?

The official website for Y-mAbs Therapeutics is www.ymabs.com.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.